Patients with epithelial ovarian cancer (EOC) face high mortality due to late diagnosis, recurrence, metastasis, and drug resistance. The NOTCH signaling pathway plays a critical role in cancer progression. This study analyzed NOTCH pathway deregulation in EOC patients and its response to taxane treatment in vitro and in vivo. In tumor cells of EOC patients, a significant upregulation of NOTCH1/3/4 and JAG2 and a downregulation of the NOTCH2 gene were found. The observed high levels of NOTCH3 mRNA were also confirmed at the protein level. In contrast, we observed a significant association of low NOTCH4 expression with the presence of peritoneal metastasis and shortened platinum-free interval. In the resistant in vitro cell line model, significant upregulation of NOTCH signaling pathway, namely NOTCH3, was observed after treatment with experimental Stony Brook taxanes (SB-Ts), with high efficacy against paclitaxel-resistant ovarian tumor cells. The administration of SB-Ts also caused NOTCH3 upregulation in an effective combination regimen with paclitaxel in comparison to paclitaxel alone and untreated control in the in vivo cell-derived xenograft mouse model of resistant ovarian cancer. Knockdown of the NOTCH3 gene caused higher sensitivity of resistant cells to taxanes, suggesting that NOTCH3-specific inhibition may potentially bring therapeutic benefits in resistant ovarian carcinoma. Based on our results, we suggest the NOTCH3 gene as a potential target for preclinical studies on resistant ovarian tumors. The current study also highlights the NOTCH4 gene as a potential predictive biomarker of therapeutic response in ovarian cancer.

Department of Gynecology and Obstetrics 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Gynecology and Obstetrics University Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Oncology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Pathology and Molecular Medicine 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Institute of Chemical Biology and Drug Discovery State University of New York at Stony Brook Stony Brook NY United States

Toxicogenomics Unit National Institute of Public Health Prague Czech Republic

Toxicogenomics Unit National Institute of Public Health Prague Czech Republic; Laboratory of Pharmacogenomics Biomedical Centre Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Zobrazit více v PubMed

Cancer of the Ovary - Cancer Stat Facts Available online: 〈https://seer.cancer.gov/statfacts/html/ovary.html〉 (accessed on 26 February 2022).

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J. Clin. 71 (2021) 209–249, 10.3322/caac.21660. PubMed DOI

Bowtell DD, Böhm S, Ahmed AA, Aspuria P-J, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et al. , Rethinking ovarian cancer II: reducing mortality from High-Grade serous ovarian cancer, Nat. Rev. Cancer 15 (2015) 668–679, 10.1038/nrc4019. PubMed DOI PMC

Rojas V, Hirshfield K, Ganesan S, Rodriguez-Rodriguez L, Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment, IJMS 17 (2016) 2113, 10.3390/ijms17122113. PubMed DOI PMC

Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C, Bouzbid S, Hamdi-Chérif M, Zaidi Z, Bah E, et al. , Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (Concord-2), Gynecol. Oncol. 144 (2017) 396–404, 10.1016/j.ygyno.2016.11.019. PubMed DOI PMC

Richardson DL, Eskander RN, O’Malley DM, Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review, JAMA Oncol. 9 (2023) 851–859, 10.1001/jamaoncol.2023.0197. PubMed DOI

Ovarian Cancer Survival | Cancer Research UK Available online: 〈https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/survival/〉 (accessed on 17 October 2024).

Kim A, Ueda Y, Naka T, Enomoto T, Therapeutic strategies in epithelial ovarian cancer, J. Exp. Clin. Cancer Res. 31 (2012) 14, 10.1186/1756-9966-31-14. PubMed DOI PMC

Kurnit KC, Fleming GF, Lengyel E, Updates and new options in advanced epithelial ovarian cancer treatment, Obstet. Gynecol. 137 (2021) 108–121, 10.1097/AOG.0000000000004173. PubMed DOI PMC

González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, et al. , Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up☆, Ann. Oncol. 34 (2023) 833–848, 10.1016/j.annonc.2023.07.011. PubMed DOI

Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, González-Martin A, Gourley C, Leary A, Lorusso D, et al. , ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease, Ann. Oncol. 35 (2024) 248–266, 10.1016/j.annonc.2023.11.015. PubMed DOI

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, et al. , ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease, Ann. Oncol. 30 (2019) 672–705, 10.1093/annonc/mdz062. PubMed DOI

Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM, Advances in ovarian cancer therapy, Cancer Chemother. Pharm. 81 (2018) 17–38, 10.1007/s00280-017-3501-8. PubMed DOI PMC

Moore KN, Pothuri B, Poly(ADP-Ribose) polymerase inhibitor inhibition in ovarian cancer: a comprehensive review, Cancer J. 27 (2021) 432–440, 10.1097/ppo.0000000000000558. PubMed DOI

Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, et al. , Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-Ov25 trial, Ann. Oncol. 34 (2023) 681–692, 10.1016/j.annonc.2023.05.005. PubMed DOI

Zaib S, Javed H, Rana N, Zaib Z, Iqbal S, Khan I, Therapeutic chemoresistance in ovarian cancer: emerging hallmarks, signaling mechanisms and alternative pathways, Curr. Med Chem. (2024), 10.2174/0109298673276871231205043417. PubMed DOI

Sahoo D, Deb P, Basu T, Bardhan S, Patra S, Sukul PK, Advancements in platinum-based anticancer drug development: a comprehensive review of strategies, discoveries, and future perspectives, Bioorg. Med Chem. 112 (2024) 117894, 10.1016/j.bmc.2024.117894. PubMed DOI

Seborova K, Koucka K, Spalenkova A, Holy P, Ehrlichova M, Sychra T, Chen L, Bendale H, Ojima I, Sandoval-Acuña C, et al. , Anticancer regimens containing third generation taxanes SB-T-121605 and SB-T-121606 are highly effective in resistant ovarian carcinoma model, Front Pharm. 13 (2022) 971905, 10.3389/fphar.2022.971905. PubMed DOI PMC

Sychra T, Spalenkova A, Balatka S, Vaclavikova R, Seborova K, Ehrlichova M, Truksa J, Sandoval-Acuña C, Nemcova V, Szabo A, et al. , Third-Generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma, iScience 27 (2024) 109044, 10.1016/j.isci.2024.109044. PubMed DOI PMC

Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, Chu Q, Notch signaling pathway: architecture, disease, and therapeutics, Sig Transduct. Target Ther. 7 (2022) 1–33, 10.1038/s41392-022-00934-y. PubMed DOI PMC

Aster JC, Pear WS, Blacklow SC, The varied roles of notch in cancer, Annu Rev. Pathol. 12 (2017) 245–275, 10.1146/annurev-pathol-052016-100127. PubMed DOI PMC

Lobry C, Oh P, Mansour MR, Look AT, Aifantis I, Notch signaling: switching an oncogene to a tumor suppressor, Blood 123 (2014) 2451–2459, 10.1182/blood-2013-08-355818. PubMed DOI PMC

Li H, Zhang W, Niu C, Lin C, Wu X, Jian Y, Li Y, Ye L, Dai Y, Ouyang Y, et al. , Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway, Int J. Cancer 145 (2019) 1921–1934, 10.1002/ijc.32293. PubMed DOI PMC

Chen M, Su J, Feng C, Liu Y, Zhao L, Tian Y, Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the Notch1 signaling pathway in ovarian cancer, Mol. Med Rep. 24 (2021) 635, 10.3892/mmr.2021.12274. PubMed DOI PMC

Zhou Y, Chen Q, Qin R, Zhang K, Li H, MicroRNA-449a reduces cell survival and enhances Cisplatin-Induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells, Tumour Biol. 35 (2014) 12369–12378, 10.1007/s13277-014-2551-3. PubMed DOI

Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama S, Otsuki Y, et al. , Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer, Am. J. Clin. Pathol. 138 (2012) 535–544, 10.1309/AJCPKDLRQ8F3EWNS. PubMed DOI

Hu W, Ivan C, Bottsford-Miller J, Zand B, Pecot C, Nick A, Stone R, Coleman R, Baggerly K, Sood A, Integrated analysis of notch pathway in high grade serous ovarian cancer, Gynecol. Oncol. 125 (2012) S7–S8, 10.1016/j.ygyno.2011.12.013. PubMed DOI PMC

Park JT, Li M, Nakayama K, Mao T-L, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih I-M, Wang T-L, Notch3 gene amplification in ovarian cancer, Cancer Res 66 (2006) 6312–6318, 10.1158/0008-5472.CAN-05-3610. PubMed DOI

Rose SL, Kunnimalaiyaan M, Drenzek J, Seiler N, Notch 1 signaling is active in ovarian cancer, Gynecol. Oncol. 117 (2010) 130–133, 10.1016/j.ygyno.2009.12.003. PubMed DOI

Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, et al. , Integrated genomic analyses of ovarian carcinoma, Nature 474 (2011) 609–615, 10.1038/nature10166. PubMed DOI PMC

Bai L, Wang A, Zhang Y, Xu X, Zhang X, Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway, Exp. Cell Res 366 (2018) 161–171, 10.1016/j.yexcr.2018.03.014. PubMed DOI

McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng K-H, et al. , Targeting notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy, Proc. Natl. Acad. Sci. 109 (2012) E2939–E2948, 10.1073/pnas.1206400109. PubMed DOI PMC

Kaye SB, Management of partially platinum-sensitive relapsed ovarian cancer, Eur. J. Cancer Suppl. 6 (2008) 16–21, 10.1016/j.ejcsup.2007.12.003. DOI

Markman M, Mekhail TM, Paclitaxel in cancer therapy, Expert Opin. Pharmacother. 3 (2002) 755–766, 10.1517/14656566.3.6.755. PubMed DOI

Pejovic T, Fitch K, Mills G, Ovarian cancer recurrence: “Is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments? Cancer Drug Resist 5 (2022) 451–458, 10.20517/cdr.2021.138. PubMed DOI PMC

Ojima I, Das M, Recent advances in the chemistry and biology of new generation taxoids, J. Nat. Prod. 72 (2009) 554–565, 10.1021/np8006556. PubMed DOI PMC

Seitz JD, Vineberg JG, Herlihy E, Park B, Melief E, Ojima I, Design, synthesis and biological evaluation of a Highly-Potent and cancer cell selective Folate-Taxoid conjugate, Bioorg. Med Chem. 23 (2015) 2187–2194, 10.1016/j.bmc.2015.02.057. PubMed DOI PMC

Seitz JD, Wang T, Vineberg JG, Honda T, Ojima I, Synthesis of a next-generation taxoid by rapid methylation amenable for 11C-labeling, J. Org. Chem. 83 (2018) 2847–2857, 10.1021/acs.joc.7b03284. PubMed DOI

Ojima I, Chen J, Sun L, Borella CP, Wang T, Miller ML, Lin S, Geng X, Kuznetsova L, Qu C, et al. , Design, synthesis, and biological evaluation of new-generation taxoids, J. Med. Chem. 51 (2008) 3203–3221, 10.1021/jm800086e. PubMed DOI PMC

Wang C, Wang X, Sun Y, Taouil AK, Yan S, Botchkina GI, Ojima I, Design, synthesis and Sar study of 3rd-generation taxoids bearing 3-CH3, 3-CF3O and 3-CHF2O groups at the C2-Benzoate position, Bioorg. Chem. 95 (2020) 103523, 10.1016/j.bioorg.2019.103523. PubMed DOI PMC

Daniel P, Balušíková K, Truksa J, Černý J, Jaček M, Jelínek M, Mulenga MJV, Voráčová K, Chen L, Wei L, et al. , Effect of substituents at the C3´, C3Ń, C10 and C2-Meta-Benzoate positions of taxane derivatives on their activity against resistant cancer cells, Toxicol. Appl. Pharm. 489 (2024) 116993, 10.1016/j.taap.2024.116993. PubMed DOI PMC

Čízková J, Filipová A, Carrillo A, Ehrlichová M, Spálenková A, Magdolenová A, Hájek M, Horák P, Erbenova A, Šinkorová Z, Simple, fast, cost-efficient, reliable, and highly automated DNA content analysis of cells in adherent cultures, Cytom. A (2024), 10.1002/cyto.a.24840. PubMed DOI

Suarez-Arnedo A, Torres Figueroa F, Clavijo C, Arbeláez P, Cruz JC, Muñoz-Camargo C, An image j plugin for the high throughput image analysis of in vitro scratch wound healing assays, PLoS One 15 (2020) e0232565, 10.1371/journal.pone.0232565. PubMed DOI PMC

Soucek P, Anzenbacher P, Skoumalová I, Dvorák M, Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells, Stem Cells 23 (2005) 1417–1422, 10.1634/stemcells.2005-0066. PubMed DOI

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, et al. , The MIQE guidelines: minimum information for publication of quantitative Real-Time PCR experiments, Clin. Chem. 55 (2009) 611–622, 10.1373/clinchem.2008.112797. PubMed DOI

Livak KJ, Schmittgen TD, Analysis of relative gene expression data using Real-Time quantitative PCR and the 2(−Delta Delta C(T)) Method, Methods 25 (2001) 402–408, 10.1006/meth.2001.1262. PubMed DOI

Özcan Ö, Belli AK, Sakallı Çetin E, Kara M, Çelik Öİ, Kaplan M, Kayılıoğlu SI, Dönmez C, Polat M, Upregulation of SIRT1 gene in gastric adenocarcinoma, Turk. J. Gastroenterol. 30 (2019) 326–330, 10.5152/tjg.2019.18550. PubMed DOI PMC

Benjamini Y, Hochberg Y, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J. R. Stat. Soc. Ser. B Methodol. 57 (1995) 289–300, 10.1111/j.2517-6161.1995.tb02031.x. DOI

Siebel C, Lendahl U, Notch signaling in development, tissue homeostasis, and disease, Physiol. Rev. 97 (2017) 1235–1294, 10.1152/physrev.00005.2017. PubMed DOI

Hu W, Lu C, Dong HH, Huang J, Shen D, Stone RL, Nick AM, Shahzad MMK, Mora E, Jennings NB, et al. , Biological roles of the delta family notch ligand Dll4 in tumor and endothelial cells in ovarian cancer, Cancer Res 71 (2011) 6030–6039, 10.1158/0008-5472.CAN-10-2719. PubMed DOI PMC

Jia D, Underwood J, Xu Q, Xie Q, NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer, Oncol. Lett. 17 (2019) 4914–4920, 10.3892/ol.2019.10170. PubMed DOI PMC

Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, Escaramis G, Jares P, Beà S, González-Díaz M, et al. , Whole-Genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature 475 (2011) 101–105, 10.1038/nature10113. PubMed DOI PMC

Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, Wang J, Zhang Y, Zhu D, Li L, Notch signaling pathway in cancer: from mechanistic insights to targeted therapies, Sig Transduct. Target Ther. 9 (2024) 1–37, 10.1038/s41392-024-01828-x. PubMed DOI PMC

Testa U, Petrucci E, Pasquini L, Castelli G, Pelosi E, Ovarian cancers: genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells, Medicines 5 (2018) 16, 10.3390/medicines5010016. PubMed DOI PMC

Lisio M-A, Fu L, Goyeneche A, Gao Z, Telleria C, High-Grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints, IJMS 20 (2019) 952, 10.3390/ijms20040952. PubMed DOI PMC

Chen B, Jiang K, Wang H, Miao L, Lin X, Chen Q, Jing L, Lu X, NOTCH pathway genes in ovarian cancer: clinical significance and associations with immune cell infiltration, Front Biosci. Landmark Ed. 28 (2023) 220, 10.31083/j.fbl2809220. PubMed DOI

Chen C, Wang X, Huang S, Wang L, Han L, Yu S, Prognostic roles of notch receptor mRNA expression in human ovarian cancer, Oncotarget 8 (2017) 32731–32740, 10.18632/oncotarget.16387. PubMed DOI PMC

Alniaimi AN, Demorest-Hayes K, Alexander VM, Seo S, Yang D, Rose S, Increased Notch1 expression is associated with poor overall survival in patients with ovarian cancer, Int J. Gynecol. Cancer 25 (2015) 208–213, 10.1097/IGC.0000000000000359. PubMed DOI

Zhu Y-T, Wu S-Y, Yang S, Ying J, Tian L, Xu H-L, Zhang H-P, Yao H, Zhang W-Y, Jin Q-Q, et al. , Identification and validation of a novel Anoikis-Related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma, Heliyon 9 (2023) e18708, 10.1016/j.heliyon.2023.e18708. PubMed DOI PMC

Zhang Z, Bu X, Yang J, Zhu S, He S, Zheng J, Wang W, Chu D, NOTCH4 regulates colorectal cancer proliferation, invasiveness, and determines clinical outcome of patients, J. Cell Physiol. 233 (2018) 6975–6985, 10.1002/jcp.26619. PubMed DOI

Yao L, Tian F, GRWD1 affects the proliferation, apoptosis, invasion and migration of triple negative breast cancer through the notch signaling pathway, Exp. Ther. Med 24 (2022) 473, 10.3892/etm.2022.11400. PubMed DOI PMC

Park JT, Chen X, Tropè CG, Davidson B, Shih I-M, Wang T-L, Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin, Am. J. Pathol. 177 (2010) 1087–1094, 10.2353/ajpath.2010.100316. PubMed DOI PMC

Kim MJ, Kim A-R, Jeong J-Y, Kim K-I, Kim T-H, Lee C, Chung K, Ko Y-H, An H-J, Correlation of ALDH1 and Notch3 expression: clinical implication in ovarian carcinomas, J. Cancer 8 (2017) 3331–3342, 10.7150/jca.18955. PubMed DOI PMC

Xu Y, Zhang Q, Miao C, Dongol S, Li Y, Jin C, Dong R, Li Y, Yang X, Kong B, CCNG1 (Cyclin G1) regulation by Mutant-P53 via induction of Notch3 expression promotes High-Grade serous ovarian cancer (HGSOC) tumorigenesis and progression, Cancer Med 8 (2019) 351–362, 10.1002/cam4.1812. PubMed DOI PMC

Liu Z, Yun R, Yu X, Hu H, Huang G, Tan B, Chen T, Overexpression of Notch3 and pS6 is associated with poor prognosis in human ovarian epithelial cancer, Mediat. Inflamm. 2016 (2016) 5953498, 10.1155/2016/5953498. PubMed DOI PMC

Zou B, Wang H, Liu Y, Qi P, Lei T, Sun M, Wang Y, Mangiferin induces apoptosis in human ovarian adenocarcinoma OVCAR3 cells via the regulation of Notch3, Oncol. Rep. 38 (2017) 1431–1441, 10.3892/or.2017.5814. PubMed DOI PMC

Gupta N, Xu Z, El-Sehemy A, Steed H, Fu Y, Notch3 induces Epithelial-Mesenchymal transition and attenuates Carboplatin-Induced apoptosis in ovarian cancer cells, Gynecol. Oncol. 130 (2013) 200–206, 10.1016/j.ygyno.2013.03.019. PubMed DOI

Kang H, Jeong J-Y, Song J-Y, Kim TH, Kim G, Huh JH, Kwon A-Y, Jung SG, An HJ, Notch3-Specific inhibition using siRNA knockdown or GSI sensitizes Paclitaxel-Resistant ovarian cancer cells, Mol. Carcinog. 55 (2016) 1196–1209, 10.1002/mc.22363. PubMed DOI

Wang W, Zhou Y, Wang J, Zhang S, Ozes A, Gao H, Fang F, Wang Y, Chu X, Liu Y, et al. , Targeting ovarian cancer stem cells by dual inhibition of the long noncoding RNA HOTAIR and lysine methyltransferase EZH2, Mol. Cancer Ther. 23 (2024) 1666–1679, 10.1158/1535-7163.MCT-23-0314. PubMed DOI PMC

Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI, Fleming GF, et al. , A phase II study of Single-Agent RO4929097, a Gamma-Secretase inhibitor of notch signaling, in patients with recurrent Platinum-Resistant epithelial ovarian cancer: a study of the princess margaret, Chicago and california phase II consortia, Gynecol. Oncol. 137 (2015) 216–222, 10.1016/j.ygyno.2015.03.005. PubMed DOI